Nektar Therapeutics Class Action Notice Issued
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy NKTR?
Source: PRnewswire
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocols in the REZOLVE-AA trial, which likely compromised the trial's integrity and misled investors, resulting in damages once the true information was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their interests in the class action and avoid inexperienced intermediaries.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NKTR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NKTR
Wall Street analysts forecast NKTR stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 74.840
Low
102.00
Averages
123.43
High
165.00
Current: 74.840
Low
102.00
Averages
123.43
High
165.00
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Nektar Therapeutics Announces Study Data for Rezpegaldesleukin
- Clinical Research Progress: Nektar Therapeutics announced that data from its Phase 2b studies of rezpegaldesleukin for atopic dermatitis and alopecia areata will be presented at the 2026 American Academy of Dermatology Annual Meeting, showcasing the company's ongoing innovation in autoimmune disease treatment.
- Efficacy and Safety: The REZOLVE-AA study results, focusing on efficacy and safety over 36 weeks for patients with severe alopecia areata, will highlight the drug's potential to improve patient quality of life, potentially opening new market opportunities for the company.
- Global Patient Recruitment: The REZOLVE-AA study enrolled patients across approximately 30 sites globally, with 62% from Poland, indicating the drug's broad applicability in different regions, which may enhance Nektar's competitiveness in international markets.
- FDA Fast Track Designation: Rezpegaldesleukin has received Fast Track designation from the FDA for the treatment of moderate-to-severe atopic dermatitis and alopecia areata, indicating its therapeutic potential and possibly accelerating the approval process, thereby enhancing the company's future revenue outlook.
See More
Nektar Therapeutics Class Action Notice Issued
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocols in the REZOLVE-AA trial, which likely compromised the trial's integrity and misled investors, resulting in damages once the true information was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their interests in the class action and avoid inexperienced intermediaries.
See More
Class Action Lawsuit Filed Against Nektar Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nektar Therapeutics, seeking damages for investors who purchased securities between February 26, 2025, and December 25, 2025, indicating serious violations of federal securities laws during this period.
- Allegations Details: The complaint alleges that Nektar's executives failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, likely leading to significant negative impacts on trial results, thus rendering the company's public statements materially false and misleading.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm Advantages: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis and has recovered hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and the importance of maintaining market integrity.
See More
Nektar Therapeutics Announces New Drug Study Progress
- Clinical Trial Data Presentation: Nektar Therapeutics will present data on rezpegaldesleukin at the 2026 American Academy of Dermatology Annual Meeting, showcasing Phase 2b results in atopic dermatitis and alopecia areata, which is expected to attract industry attention and enhance the company's visibility.
- Efficacy and Safety Research: The study on alopecia areata demonstrates significant efficacy and safety after 36 weeks of treatment with rezpegaldesleukin, potentially offering a new treatment option for patients inadequately controlled by other therapies, thereby enhancing market competitiveness.
- Global Patient Recruitment: The REZOLVE-AA study recruited patients across approximately 30 sites globally, with 62% from Poland, 24% from Canada, and 14% from the United States, showcasing Nektar's extensive international reach and research diversity.
- FDA Fast Track Designation: Rezpegaldesleukin has received FDA Fast Track designation for atopic dermatitis and alopecia areata, indicating its therapeutic potential and possibly accelerating the approval process, which could enhance the company's future revenue outlook.
See More
Nektar Therapeutics Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR), encouraging those who purchased shares between February 26, 2025, and December 15, 2025, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Details: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards, likely leading to significant negative impacts on trial results and damaging the company's reputation.
- Key Deadline: Shareholders must register by May 5, 2026, to participate in the class action lawsuit, and failure to register in time may result in the loss of the right to claim, highlighting the urgency of the legal process.
- Participation Method: Once registered, shareholders will be enrolled in a portfolio monitoring software that provides status updates throughout the lifecycle of the case, with no cost or obligation to participate, reflecting the accessibility of legal services.
See More
Investment Opportunities in Abivax and Nektar Therapeutics
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
See More
Nektar Therapeutics Announces Study Data for Rezpegaldesleukin
- Clinical Research Progress: Nektar Therapeutics announced that data from its Phase 2b studies of rezpegaldesleukin for atopic dermatitis and alopecia areata will be presented at the 2026 American Academy of Dermatology Annual Meeting, showcasing the company's ongoing innovation in autoimmune disease treatment.
- Efficacy and Safety: The REZOLVE-AA study results, focusing on efficacy and safety over 36 weeks for patients with severe alopecia areata, will highlight the drug's potential to improve patient quality of life, potentially opening new market opportunities for the company.
- Global Patient Recruitment: The REZOLVE-AA study enrolled patients across approximately 30 sites globally, with 62% from Poland, indicating the drug's broad applicability in different regions, which may enhance Nektar's competitiveness in international markets.
- FDA Fast Track Designation: Rezpegaldesleukin has received Fast Track designation from the FDA for the treatment of moderate-to-severe atopic dermatitis and alopecia areata, indicating its therapeutic potential and possibly accelerating the approval process, thereby enhancing the company's future revenue outlook.
See More
Nektar Therapeutics Class Action Notice Issued
- Class Action Timeline: Rosen Law Firm reminds investors who purchased Nektar Therapeutics (NASDAQ:NKTR) securities between February 26, 2025, and December 15, 2025, that they must apply to be lead plaintiff by May 5, 2026, to participate in the class action and seek compensation.
- Lawsuit Background: The lawsuit alleges that defendants failed to adhere to applicable instructions and protocols in the REZOLVE-AA trial, which likely compromised the trial's integrity and misled investors, resulting in damages once the true information was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS for the number of securities class action settlements in 2017, showcasing its expertise and success in this field.
- Participation Instructions: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, ensuring they select qualified legal counsel to protect their interests in the class action and avoid inexperienced intermediaries.
See More
Class Action Lawsuit Filed Against Nektar Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Nektar Therapeutics, seeking damages for investors who purchased securities between February 26, 2025, and December 25, 2025, indicating serious violations of federal securities laws during this period.
- Allegations Details: The complaint alleges that Nektar's executives failed to follow applicable instructions and protocol standards in the REZOLVE-AA trial, likely leading to significant negative impacts on trial results, thus rendering the company's public statements materially false and misleading.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by May 5, 2026, to share in any potential recovery, with the assurance that participation does not require serving as lead plaintiff.
- Law Firm Advantages: Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis and has recovered hundreds of millions for investors nationwide, emphasizing its expertise in securities fraud class actions and the importance of maintaining market integrity.
See More
Nektar Therapeutics Announces New Drug Study Progress
- Clinical Trial Data Presentation: Nektar Therapeutics will present data on rezpegaldesleukin at the 2026 American Academy of Dermatology Annual Meeting, showcasing Phase 2b results in atopic dermatitis and alopecia areata, which is expected to attract industry attention and enhance the company's visibility.
- Efficacy and Safety Research: The study on alopecia areata demonstrates significant efficacy and safety after 36 weeks of treatment with rezpegaldesleukin, potentially offering a new treatment option for patients inadequately controlled by other therapies, thereby enhancing market competitiveness.
- Global Patient Recruitment: The REZOLVE-AA study recruited patients across approximately 30 sites globally, with 62% from Poland, 24% from Canada, and 14% from the United States, showcasing Nektar's extensive international reach and research diversity.
- FDA Fast Track Designation: Rezpegaldesleukin has received FDA Fast Track designation for atopic dermatitis and alopecia areata, indicating its therapeutic potential and possibly accelerating the approval process, which could enhance the company's future revenue outlook.
See More
Nektar Therapeutics Shareholder Class Action Notice
- Lawsuit Background: The Gross Law Firm has issued a notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR), encouraging those who purchased shares between February 26, 2025, and December 15, 2025, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Details: The complaint alleges that during the class period, defendants made materially false and/or misleading statements and failed to disclose that enrollment in the REZOLVE-AA trial did not follow applicable instructions and protocol standards, likely leading to significant negative impacts on trial results and damaging the company's reputation.
- Key Deadline: Shareholders must register by May 5, 2026, to participate in the class action lawsuit, and failure to register in time may result in the loss of the right to claim, highlighting the urgency of the legal process.
- Participation Method: Once registered, shareholders will be enrolled in a portfolio monitoring software that provides status updates throughout the lifecycle of the case, with no cost or obligation to participate, reflecting the accessibility of legal services.
See More
Investment Opportunities in Abivax and Nektar Therapeutics
- Potential Blockbuster for Abivax: Abivax is developing obefazimod for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis, with top-line data expected in Q2; if successful, it could lead to regulatory approval and tap into a market projected to reach $14.3 billion by 2035.
- Acquisition Rumors Boost Stock: Despite a 10% decline this year, Abivax's stock has surged over 1,900% in the past year, driven by strong clinical results and acquisition rumors from Eli Lilly and AstraZeneca, suggesting that a buyout could occur at a premium to current prices.
- Strong Cash Position: As of Q3 2025, Abivax reported €589.7 million (approximately $697 million) in cash, sufficient to fund operations into Q4 2027, indicating robust financial health.
- Nektar's Promising Therapy: Nektar's rezpegaldesleukin showed over 80% of patients achieving at least 75% skin improvement in a phase 2b trial for moderate-to-severe atopic dermatitis, positioning it as a strong competitor in the eczema market against established therapies like Dupixent.
See More
